CRC Research Update — September 14, 2026
Today's colorectal cancer research highlights
kras
A collection of 71 issues
Pooled Analysis Examines Prognostic Value of KRAS Mutations and Liver Metastases
Skip to content
The CRC Digest
Pooled Analysis Examines Prognostic Value of KRAS Mutations and Liver Metastases
A pooled analysis of third-line placebo-controlled trials from the ARCAD CRC Database evaluated the prognostic impact of liver metastases and KRAS mutations in metastatic colorectal cancer patients. (Clinical Colorectal Cancer)
This content is
CRC Research Update — September 13, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 09, 2026
Today's colorectal cancer research highlights
KRAS Mutations Shape Immunosuppressive Tumor Environment
Skip to content
The CRC Digest
◇ RESEARCH
KRAS Mutations Shape Immunosuppressive Tumor Environment
A review describes how KRAS mutations—present in approximately 52% of colorectal cancers—actively create an immunosuppressive tumor microenvironment, presenting a major barrier to both targeted therapy and immunotherapy. (Frontiers in Oncology)
This content is informational only
CRC Research Update — September 05, 2026
Today's colorectal cancer research highlights
KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth
Skip to content
The CRC Digest
◇ RESEARCH
KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth
A study in KRAS-mutant CRC patients and mice found that KRAS reshapes the microbial community, enriching Bacteroides acidifaciens, which predicts poor prognosis and promotes malignant phenotypes in KRAS-mutant tumors. (Cell Host & Microbe)
This
Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC
Skip to content
The CRC Digest
◇ RESEARCH
Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC
Analysis of 6,762 samples across four age groups found that early-onset colorectal cancer (diagnosed before age 50) shows different mutation patterns compared to later-onset disease, with implications for testing guidelines and therapeutic development.
CRC Research Update — September 04, 2026
Today's colorectal cancer research highlights
Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC
Skip to content
The CRC Digest
◇ RESEARCH
Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC
Researchers developed sulfasalazine-loaded hafnium oxide nanoparticles (HfO2@SAS) to overcome radiotherapy resistance in KRAS-mutant colorectal cancer by targeting the SLC7A11/GPX4 pathway and inducing ferroptosis (a form of cell death). (Biomaterials)
This content is informational only